http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-036391-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf82b2c04febd9f5fc6ead8595272b9a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
| filingDate | 2002-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a69df437bc5509867460c655d0bf2e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_230b08160c80fe23de9be8b04e01cc8e |
| publicationDate | 2004-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-036391-A1 |
| titleOfInvention | USE OF A PROSTAGLANDINE COMPOSITE TO PREPARE A PHARMACEUTICAL COMPOSITION TO OPEN CIC CHANNELS IN A MAMMER AND PROSTAGLANDINE COMPOUNDS |
| abstract | Use of a prostaglandin compound to prepare a pharmaceutical composition to open the CIC channels in a mammal, wherein said compound is represented by the general formula (1), where L, M and N are hydrogen atom, hydroxy, atom of halogen, lower alkyl, hydroxyalkyl (lower) or oxo, where at least one of L and M is a different group of hydrogen, and the five-membered ring may have at least one double bond; A is -CH2OH, -COCH2OH, -COOH or a functional derivative thereof; B is -CH2-CH2-, -CH = CH- or C ::: C; Z is formula (2), where R4 and R5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxyalkyl (lower), where R4 and R5 are not hydroxy and lower alkoxy at the same time; R1 is a lower aliphatic hydrocarbon residue or saturated or unsaturated bivalent medium that is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one of the carbon atoms in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a lower aliphatic or saturated or unsaturated medium hydrocarbon residue that is unsubstituted or substituted by halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cycloalkyl (lower), cycloalkyloxy (lower), aryl, aryloxy, heterocyclic group or group heterocyclic-oxy; cycloalkyl (lower); cycloalkyloxy (lower), aryl; aryloxy; heterocyclic group; heterocyclic-oxy group. A compound represented by the formula (3) where L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxyalkyl (lower) or oxo, where at least one of L and M is a group other than hydrogen, and the ring Five-member can have one or more double links; R 'and R' 'are hydrogen, lower alkyl, aryl, alkyl or aryl sulfonyl, lower alkenyl or lower alkynyl; B is -CH2-CH2-, -CH = CH- or -C ::: C-; R1 is a lower aliphatic hydrocarbon residue or saturated or unsaturated bivalent medium that is unsubstituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a lower aliphatic or saturated or unsaturated medium hydrocarbon residue that is unsubstituted or substituted by halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cycloalkyl (lower), cycloalkyloxy (lower), aryl, aryloxy, heterocyclic group or group heterocyclic-oxy; cycloalkyl (lower); cycloalkyloxy (lower); aryl; aryloxy; heterocyclic group; heterocyclic-oxy group. The mentioned pharmaceutical composition is useful for treating a condition associated with a reduced permeability of the chloride ion in a mammal, the same being preferably a cystic fibrosis. |
| priorityDate | 2001-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.